Sino Biological Launches 4RISE™ High-Throughput Wet-Lab Services to Accelerate AI-Driven Drug Discovery
Found this article helpful?
Share it with your network and spread the knowledge!

Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, announced the launch of its 4RISE™ high-throughput wet-lab validation services for AI-designed protein binders. The services are designed to bridge the gap between computational protein design and experimental validation, offering 3-hour cell-free expression, AI-ready binding data in as little as 3 days, and real-time API access to structured target-binding data. The announcement, made via NEWMEDIAWIRE, highlights a growing need in the life sciences industry to verify AI-generated designs quickly and reliably.
AI-driven protein design is accelerating the discovery of novel protein binders, but experimental validation remains essential to determine whether computational designs translate into meaningful target interactions. Sino Biological’s 4RISE™ platform addresses this by combining rapid experimental turnaround, scalable screening workflows, and structured data delivery to support continuous design-test-learn cycles. The XPressMAX™ Cell-Free Protein Synthesis (CFPS) platform enables recombinant protein synthesis in just 3 hours, with expression success rates exceeding 99% in established workflows. This allows researchers to test AI-designed candidates faster and iterate designs more efficiently.
Using Carterra high-throughput SPR, Biacore SPR, and Octet BLI, 4RISE™ delivers high-throughput binding screening, kinetic analysis, and affinity determination. Combined with CFPS, the workflow delivers sequence-to-AI-ready binding data in as little as 3 days. Structured binding data are accessible in real time via API, enabling seamless data retrieval for downstream research and analysis. The services offer four rapid screening options: Rapid Hit Discovery for miniproteins and VHHs, Comparative Binder Screening for candidate prioritization, Affinity & Kinetic Characterization for lead selection, and Specialized Binder Expression & Validation for diverse formats. Beyond binding, 4RISE™ provides 20+ developability assays, 1,000+ protein bioactivity assays, and 10+ cell-based functional assays.
For Texas, the launch matters because Sino Biological has a U.S. presence in Houston, positioning the state as a node in the AI-driven drug discovery ecosystem. The services could benefit Texas-based biotech companies and research institutions working on AI-designed therapeutics by providing faster validation cycles and high-quality data. “AI-designed molecules need reliable wet-lab experimental evidence to demonstrate their potential,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. “Our integrated capabilities provide the high-quality data researchers need to evaluate candidates quickly, shorten design cycles, and turn promising discoveries into real-world applications.”
Researchers interested in the services can Explore 4RISE™ High-Throughput Wet-Lab Validation Services Now! More details are available through the company’s website at www.sinobiological.com. The original release can be viewed on www.newmediawire.com.
